These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 29063377

  • 1. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO, Khalafallah NM, Molokhia AM, Elsayed MMA.
    AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
    [Abstract] [Full Text] [Related]

  • 2. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 3. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J, Ma S, He X, Sun Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2023 Jul 25; 642():123179. PubMed ID: 37364785
    [Abstract] [Full Text] [Related]

  • 6. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS, Kim JH, Jin SG, Kim DW, Kim JO, Yong CS, Youn YS, Oh KT, Woo JS, Choi HG.
    Pharm Dev Technol; 2018 Feb 25; 23(2):158-166. PubMed ID: 28612675
    [Abstract] [Full Text] [Related]

  • 7. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2010 Nov 25; 76(3):464-9. PubMed ID: 20854906
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insights into the potential of rheological measurements in development of dry powder inhalation formulations.
    Almansour K, Alfagih IM, Shalash AO, Brockbank K, Ali R, Freeman T, Elsayed MMA.
    Int J Pharm; 2022 Feb 25; 614():121407. PubMed ID: 34942326
    [Abstract] [Full Text] [Related]

  • 12. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
    Kinnunen H, Hebbink G, Peters H, Shur J, Price R.
    AAPS PharmSciTech; 2014 Aug 25; 15(4):898-909. PubMed ID: 24756910
    [Abstract] [Full Text] [Related]

  • 13. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ, Kim SH, Raman V, Smyth HD.
    J Pharm Sci; 2012 Mar 25; 101(3):1097-107. PubMed ID: 22095397
    [Abstract] [Full Text] [Related]

  • 14. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 25; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 15. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
    Elsayed MMA, Alfagih IM, Brockbank K, Aodah AH, Ali R, Almansour K, Shalash AO.
    Int J Pharm; 2024 Apr 25; 655():123966. PubMed ID: 38452834
    [Abstract] [Full Text] [Related]

  • 16. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T, Tong S, Liao Q, Pan L, Cheng M, Rantanen J, Cun D, Yang M.
    Int J Pharm; 2023 Mar 25; 635():122702. PubMed ID: 36773729
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P, Du J, Smyth HDC.
    J Pharm Sci; 2017 Jan 25; 106(1):366-376. PubMed ID: 27939234
    [Abstract] [Full Text] [Related]

  • 18. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ, Chan LW, Heng PWS.
    Mol Pharm; 2018 Apr 02; 15(4):1635-1642. PubMed ID: 29490144
    [Abstract] [Full Text] [Related]

  • 19. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO, Elsayed MMA.
    AAPS PharmSciTech; 2017 Nov 02; 18(8):2862-2870. PubMed ID: 28421352
    [Abstract] [Full Text] [Related]

  • 20. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M, Schwarz E, Kobler M, Hauptstein S, Steckel H, Scherließ R.
    Int J Pharm; 2018 Jan 15; 535(1-2):59-67. PubMed ID: 29100914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.